{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Hispanic/Latino",
      "underserved",
      "vaccine effectiveness",
      "variants"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36706204",
  "DateCompleted": {
    "Year": "2023",
    "Month": "01",
    "Day": "31"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "02",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "02",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "2327-2228",
      "JournalIssue": {
        "Volume": "106",
        "Issue": "1",
        "PubDate": {
          "Year": "2023",
          "Month": "Feb",
          "Day": "01"
        }
      },
      "Title": "Rhode Island medical journal (2013)",
      "ISOAbbreviation": "R I Med J (2013)"
    },
    "ArticleTitle": "BNT162b2 and mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population.",
    "Pagination": {
      "StartPage": "26",
      "EndPage": "28",
      "MedlinePgn": "26-28"
    },
    "Abstract": {
      "AbstractText": [
        "The real world COVID-19 vaccine effectiveness among the urban underserved Hispanic/Latino populations is unknown. We evaluated the mRNA vaccine effectiveness in preventing SARS-CoV-2 infections at a major federally qualified health center in Providence, Rhode Island, and a total of 38,602 patients were included. Time period was used as the SARS-CoV-2 variant proxy. Compared to the unvaccinated group, the adjusted vaccine effectiveness for 2 doses of BNT162b2 and mRNA-1273 were 94.6% and 97.5% respectively against the alpha variant/wild type, which dropped to 64.8% and 65.0% respectively against the delta variant and 31.6% and 25.6% respectively against the omicron variant. However, once received the booster dose (3rd dose) of BNT162b2 and mRNA-1273, the vaccine effectiveness against the omicron variant improved to 79.9% and 71.2% respectively. Improving the COVID-19 vaccine education and encouraging to receive a booster dose may help further reduce the burden of SARS-CoV-2 infection in this population."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Brown University Warren Alpert Medical School, Providence, RI."
          }
        ],
        "LastName": "Weng",
        "ForeName": "Chien-Hsiang",
        "Initials": "CH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Yale University School of Medicine, New Haven, CT."
          }
        ],
        "LastName": "Zhou",
        "ForeName": "Sheng",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Providence Community Health Centers, Providence, R."
          }
        ],
        "LastName": "Saal",
        "ForeName": "Andrew",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Providence Community Health Centers, Providence, RI."
          }
        ],
        "LastName": "Hafferty",
        "ForeName": "Mallory",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Providence Community Health Centers, Providence, RI."
          }
        ],
        "LastName": "McGuire",
        "ForeName": "Daniel C",
        "Initials": "DC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Warren Alpert Medical School of Brown University and Rhode Island Department of Health, Providence, RI."
          }
        ],
        "LastName": "Chan",
        "ForeName": "Philip A",
        "Initials": "PA"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "R I Med J (2013)",
    "NlmUniqueID": "101605827",
    "ISSNLinking": "0363-7913"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "BNT162 Vaccine"
    },
    {
      "RegistryNumber": "EPK39PL4R4",
      "NameOfSubstance": "2019-nCoV Vaccine mRNA-1273"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "BNT162 Vaccine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "2019-nCoV Vaccine mRNA-1273"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccine Efficacy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vulnerable Populations"
    }
  ]
}